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Summary
Objective: To investigate the expression and activity of PPAR in human synovial Þbroblasts and the effects of PPAR agonists on the
expression of MMP-1. The molecular mechanisms by which PPAR agonists modulate MMP-1 expression were also examined.
Methods: PPAR expression and activity were measured using reverse-transcription polymerase chain reaction (RT-PCR) and transient
transfection assays. Human synovial Þbroblasts were cultured with IL-1 in the absence or presence of PPAR activators, and the
expression and production of MMP-1 were evaluated by Northern blot and ELISA, respectively. The effect of 15d-PGJ2 on MMP-1 promoter
activation was analysed in transient transfection experiments, while electrophoretic mobility shift assays were performed to study the binding
activity of the transcription factor AP-1.
Results: PPAR was expressed and transcriptionally functional in human synovial Þbroblasts. PPAR activators (15d-PGJ2 and BRL 49653)
inhibited IL-1-induced MMP-1 synthesis in a dose-dependent manner. Similarly, both activators inhibited IL-1-induced MMP-1 mRNA
expression. Activation of the human MMP-1 promoter was also attenuated by 15d-PGJ2, indicating that the inhibitory effect of 15d-PGJ2
occurs at the transcriptional level. Interestingly, 15d-PGJ2 reduced both basal and IL-1-induced AP-1 binding activity.
Conclusions: These data indicate that PPAR agonists inhibit MMP-1 gene expression by transcriptional mechanisms, and suggest that they
may be useful in reducing joint tissue destruction. © 2002 OsteoArthritis Research Society International
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Articular joint tissue degradation is an important event in
arthritic diseases such as osteoarthritis (OA) and rheuma-
toid arthritis (RA)1. The destruction of cartilage and bone is
thought to be largely mediated by proteases belonging to
the matrix metalloproteinases (MMP) family. One member,
the interstitial collagenase 1 (MMP-1), is largely respon-
sible for the destruction of articular joint tissue since it
degrades native collagens, i.e. types I, II, and III collagen2.
An elevated level has been evidenced in the synovial
membrane, synovial ßuid, and cartilage from humans diag-
nosed with OA and RA3. This MMP is produced by synovial
Þbroblasts in the synovial membrane intimal lining, and by
macrophages and chondrocytes46. MMP-1 production is
potently up-regulated by tumour promoters, growth factors
and proinßammatory cytokines such as interleukin-1 (IL-
1) and tumour necrosis factor- (TNF-)79.
The expression of MMP-1 is controlled mainly at the
transcriptional level, and characterization of the MMP-1100gene promoter has revealed that AP-1 is an essential
transcription factor of its induction1013. In addition, AP-1 is
required for the expression of all members of the MMP
family, with the exception of human gelatinase A and
stromelysin-314,15.
The identiÞcation of pathways involved in the negative
control of MMP-1 production and activity constitutes a
growing Þeld of interest. Indeed, an understanding of the
process of joint protective mechanisms that occur physio-
logically would be of substantial aid in the design of new
pharmacological strategies. In this regard, MMP-1 biologi-
cal activity is down-regulated physiologically by speciÞc
tissue inhibitors of MMP, named TIMP16,17; however, little is
known about the endogenous molecular signals involved in
inhibiting MMP-1 gene expression.
A potential candidate in down-regulating MMP gene
expression is the peroxisome proliferator-activated recep-
tor  (PPAR), a member of the nuclear receptor family. It
was originally characterized as a regulator of adipocyte
differentiation and lipid metabolism18,19. Recently, PPAR
was also shown to be expressed in other cell types,
including macrophages, T lymphocytes, endothelial cells
and chondrocytes2024. Ligands for PPAR include
certain polyunsaturated fatty acids, the thiazolidinedione
class of antidiabetic drugs, a variety of nonsteroidal anti-
inßammatory drugs (NSAID) and the prostaglandin D2
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REAGENTS
The following reagents were from Gibco BRL-Life Tech-
nologies (Burlington, ON, Canada): Dubelccos ModiÞed
Eagles Medium (DMEM), Trizol, heat inactivated fetal calf
serum (FCS), and an antibiotic mixture (10,000 units/ml
of penicillin, 10,000 g/ml of streptomycin). Phorbol
12-myristate 13-acetate (PMA), sodium ßuoride, leupetin,
aprotinin, pepstatin, phenylpethysulphonylßuoride (PMSF)
and dithiothreiol (DTT) were from Sigma-Aldrich Canada
(Oakville, ON, Canada). Human recombinant IL-1 (IL-1)
was obtained from Genzyme (Cambridge, MA). 15d-PGJ2
was purchased from Cayman Chemical (Ann Arbor, MI).
BRL 49653 was from American Radiolabeled Chemicals,
Inc (St Louis, MO). All other chemicals were purchased
from Fisher ScientiÞc (Nepean, ON, Canada).SPECIMEN SELECTION AND SYNOVIAL FIBROBLAST CULTURES
Synovial membrane specimens were obtained from 22
OA patients (mean age±S.E.M., 69.5±9.7 years) undergoing
total knee joint replacement. All OA patients were evaluated
by a certiÞed rheumatologist and diagnosed on the criteria
developed by the ACR Diagnostic Subcommittee for OA30.
Post-surgery, specimens were kept on ice and aseptically
processed as previously described31. Brießy, synovial Þbro-
blasts were released by sequential enzymatic digestion
with 1 mg/ml pronase (Boehringer Mannheim Canada,
Laval, QC, Canada) for 1 h, followed by 6 h with 2 mg/ml
collagenase (TypeIA, Sigma) at 37°C in DMEM supple-
mented with 10% FCS, 100 units/ml penicillin and 100 g/
ml streptomycin. Released synovial Þbroblasts wereincubated for 1 h at 37°C in tissue culture ßasks (Primaria
#3824, Falcon, Lincoln Park, NJ) allowing for the adher-
ence of nonÞbroblastic cells possibly present in the cell
preparation. Flow cytometric analysis (Epic II, Coulter,
Miami, FL), using the anti-CD14 (ßuorescein isothiocy-
anate, FITC) antibody conÞrmed that no monocyte/
macrophages were present in the synovial Þbroblast
preparations. The cells were seeded in tissue culture
ßasks, and cultured until conßuence in DMEM supple-
mented with 10% FCS and antibiotics at 37°C in a humidi-
Þed atmosphere of 5% CO2/95% air. Cells between
passages 4 and 7 were used.QUANTIFICATION OF MMP-1 PROTEIN
Synovial Þbroblasts were plated on a 24-well culture dish
(Falcon, Lincoln Park, NJ) at a number of 2×105 cells per
well in DMEM containing 10% FCS. After 48 h, the medium
was replaced with fresh DMEM containing 1% FCS, and
the cells were treated with IL-1 (100 pg/ml) alone, or with
IL-1 and various concentrations of PPAR agonists (the
15d-PGJ2 and BRL49653). The supernatants were col-
lected after a 24 h incubation period. MMP-1 protein levels
were quantitated in conditioned media by a speciÞc
enzyme-linked immunosorbent assay (ELISA; R&D
Systems Inc, Minneapolis, MN) according to the manu-
facturers protocol. This ELISA permits the measurement of
the pro- and active forms of MMP-1. All assays were
performed in duplicate.RNA EXTRACTION AND REVERSE TRANSCRIPTASE-POLYMERASE
CHAIN REACTION (RT-PCR)
Total RNA from cultured synovial Þbroblasts was isolated
by the single-step guanidinium thiocyanate-phenol-
chloroform method with the use of Trizol (Gibco BRL-Life
Technologies). Two micrograms of total RNA were reverse-
transcribed into cDNA as previously described32. AmpliÞca-
tion of the partial cDNA encoding PPAR or GADPH were
performed using speciÞc oligonucleotide primers as fol-
lows: PPAR sense 5′TCTCTCCGTAATGGAAGACC-3′
and antisense 5′-GCATTATGAGACATCCCCAC-3′, and
GAPDH sense 5′-ACCACAGTCCATGCCATCAC-3′ and
antisense 5′TCCACCACCCTGTTGCTGTA-3′. The assays
were run for 35 cycles, each cycle consisting of 30 seconds
at 94°C and 1 minute at 60°C, with a Þnal elongation step at
60 °C for 8 min with Taq polymerase32. The expected sizes
of the PCR products for PPAR and GAPDH were 474 and
452 base pairs, respectively. Controls for reverse transcrip-
tion were included. The PCR products were separated on a
2% agarose gel and stained with ethidium bromide.PLASMIDS AND TRANSIENT TRANSFECTIONS
The PPRE-luciferase construct containing three PPAR-
responsive elements (PPRE) cloned upstream of the thy-
midine kinase promoter (PPRE-Tk-Luciferase) was
generously provided by Dr C. K. Glass (University of
California, San Diego, CA). The human PPAR expression
vector was a gift from Dr S. A. Kliewer (Glaxo, Research
Triangle Park, NC). The plasmid SV40--galactosidase
(Promega, Madison, WI) was used as an internal control.
The human MMP-1 promoter/luciferase reporter plasmid
(-512hMMP-1-Luc) has been previously described33 and




Recent studies have documented the role of PPAR
ligands as antiinßammatory agents. They showed that
15d-PGJ2 and synthetic PPAR ligands inhibited the
expression of a number of genes involved in inßammatory
responses in monocytes and activated macrophages20,28.
Clark et al.21 have shown that PPAR activators inhibit T
cell proliferation as well as IL-2 secretion, indicating that it
may play a critical role, not only in the innate, but also in the
adaptive immune system. In addition, an anti-inßammatory
role for PPAR ligands has been described in joint connec-
tive tissue cells. PPAR has been shown to be expressed in
human and rat chondrocytes, and PPAR ligands inhibit the
IL-1-induced nitric oxide (NO) and MMP-13 production, as
well as a decrease of proteoglycan synthesis23,24. On the
other hand, Mbalaviele et al.29 reported that 15d-PGJ2
inhibits osteoclast differentiation through stimulation of
PPAR.
In this study, we investigated the expression of PPAR in
human synovial Þbroblasts, and examined whether PPAR
activators may modulate the expression of MMP-1. We
report that PPAR is expressed in these cells, and provide
evidence that two PPAR ligands do inhibit IL-1-induced
MMP-1 gene expression as well as its production. This
inhibition is regulated at the transcriptional level and
occurs, at least in part, by preventing the binding of AP-1
proteins to their target sequence. These data suggest that
targeted modulation of the PPAR pathway may offer a
novel approach for therapeutic inhibition of joint tissue
degradation.
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tains two AP-1 binding sequences, which are required for
MMP-1 inducibility.
Human synovial Þbroblasts at 5060% conßuence were
transiently transfected with FuGene-6 transfection reagent
(Roche Diagnostics, Laval, QC, Canada) according to the
manufacturers instructions. Brießy, 15 l of FuGene-6 were
added to 285 l of serum-free DMEM and incubated for
5 min at room temperature. Subsequently, the mixture was
added dropwise to the DNA, and after 15 min at room
temperature, the DNA/FuGene-6 mixture was added to the
cells. Six hours later, the medium was replaced with DMEM
containing 1% FCS. After an 18 h incubation, the cells were
treated for another 16 h in the presence or absence of
10 M 15d-PGJ2 or 100 M BRL 14953. Cells were lysed in
reporter lysis buffer (Promega). -galactosidase content
was determined using a -galactosidase assay kit
(Boehringer Manneheim), and luciferase activity by a
luciferase kit (Promega).NORTHERN BLOTTING ANALYSIS
Total RNA was extracted as described above and
resolved on 1.2% formaldehyde-agarose gels, then trans-
ferred electrophoretically to nylon membranes (Hybond-N;
Amersham Life Science, Oakville, ON, Canada) in a 10 mM
sodium acetate buffer, pH 7.8, 20 mM Tris, and 0.5 mM
EDTA overnight at 4°C. The RNA was cross-linked to the
membrane by exposure to ultraviolet light. After pre-
hybridization for 24 h, hybridizations were carried out at
68°C with an MMP-1 RNA probe. The probe was prepared
from a human MMP-1 full-length cDNA, generously pro-
vided by Dr D. Edwards (University of Calgary, AB,
Canada). The probe was labeled with digoxigenin-11UTP
(DIG-11-UTP; Boehringer Mannheim) according to the
manufacturers speciÞcations. Detection was carried out by
chemiluminescence with the CDP* substrate and exposure
to Kodak X-AR5 Þlm (Eastman Kodak, Rochester, NY).
After the Þrst hybridization, the membrane was stripped
and rehybridized with a DIG-labeled probe speciÞc for
GAPDH.
The autoradiographs were scanned using the imaging
system ChemiImager 4000 (Alpha Innotech, San Leandro,
CA), and the messenger RNA (mRNA) values were calcu-
lated as the relative expression of MMP-1 normalized to
GAPDH mRNA.EXTRACTION OF NUCLEAR PROTEINS AND ELECTROPHORETIC
MOBILITY SHIFT ASSAY (EMSA)
Synovial Þbroblasts were pretreated with vehicle (methyl
acetate; Fisher, ON, Canada) or 15d-PGJ2 for 2 h, and then
incubated with IL-1 (100 pg/ml) for 1 h. The nuclear pro-
teins were obtained as previously described31. Brießy,
synovial Þbroblasts were washed in ice-cold PBS and
gently scraped in ice-cold hypotonic buffer containing
10 mM HEPES-KOH, pH 7.9, 10 mM KCl, 1.5 mM MgCl2,
0.5 mM DTT, 1 mM PMSF, 1 mM Na3VO4 and 10 g/ml of
aprotinin, leupeptin and pepstatin. The cells were allowed
to swell on ice and the nuclei were recovered by brief
centrifugation. The pellets were resuspended in a high salt
extraction buffer containing 20 mM HEPES, pH 7.9,
420 mM NaCl, 1.2 mM MgCl2, 0.5 mM DTT, 0.2 mM EDTA,
25% glycerol, 0.5 mM PMSF, 1 mM Na3VO4 and 10 g/ml
each of aprotinin, leupeptin and pepstatin, followed byincubation on ice for 20 min. The nuclear extracts were
recovered by centrifugation, the protein levels determined,
and the supernatant fractions stored at −80°C until used. A
synthetic double-stranded oligonucleotide, corresponding
to the proximal MMP-1 AP-1 binding site (5′-TAAGTGA
TGACTCACCATTGC-3′), was end-labeled by T4 polynu-
cleotide kinase in the presence of [-32P]ATP. The mutant
competitor oligonucleotide had the following sequence with
a 2-bp substitution (underlined): 5′- TAAGTGATGACTT
GCCATTGC-3′. The binding buffer consisted of 10 mM
Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM DTT, 0.5 mM EDTA,
1 mM MgCl2, 4% glycerol and 2.5 g poly (dI-dC). Binding
reactions were conducted with 5 g nuclear extract and
100,000 cpm [-32P]ATP-labeled oligonucleotide probe at
22°C for 20 min in a Þnal volume of 10 l. Binding com-
plexes were resolved on nondenaturating 6% polyacryla-
mide gel electrophoresis in a Tris-borate buffer system,
after which the gels were Þxed, dried and prepared for
autoradiography.STATISTICAL ANALYSIS
All results were expressed as the mean±S.E.M. of inde-
pendent experiments. Statistics were done using a two-
tailed Students t-test. P values less than 0.05 were
considered signiÞcant.ResultsPPAR IS EXPRESSED AND TRANSCRIPTIONALLY ACTIVE IN HUMAN
SYNOVIAL FIBROBLAST CELLS
Expression of PPAR mRNA in human synovial Þbro-
blast cells was investigated using speciÞc primers for
PPAR. RT-PCR using RNA from cultured synovial Þbro-
blasts, derived from three different donors, yielded the
474-bp cDNA product expected [Fig. 1(a)].
To determine whether PPAR receptors are transcrip-
tionally active in human synovial Þbroblasts, cells were
transiently transfected with a PPAR-responsive element
cloned upstream of the luciferase gene (PPREx3-tk-
luciferase), and treated with two PPAR speciÞc activators:
15d-PGJ2 (10 M) and BRL 49653 (100 M). As shown in
Fig. 1(b) (N=3), transiently transfected PPREx3-tk-Luc is
activated 3- to 5-fold by 15d-PGJ2 (4.2±0.6, mean±S.E.M.;
P<0.01) and 2.5- to 3.5-fold by BRL 49653 [2.9±0.3,
mean±S.E.M.; P<0.01; Fig. 1(b)]. Together, these data
strongly suggest that PPAR receptors are present and
functional in human synovial Þbroblasts.PPAR LIGANDS DECREASE IL-1-INDUCED MMP-1 PRODUCTION
Because elevated levels of MMP-1 have been implicated
in the destruction of joint tissues in arthritis, we determined
the effect of PPAR activators on MMP-1 production in
synovial Þbroblasts. Cells were exposed to 100 pg/ml IL-1
and increasing concentrations of 15d-PGJ2 for 18 h, and
the amount of MMP-1 in the conditioned media determined.
Data showed that 15d-PGJ2 dose-dependently reduced
MMP-1 production, with an EC50 of about 35 mM [Fig.
2(a)], which is near the Kd of 15d-PGJ2 binding to
PPAR25,34. BRL 49653, a synthetic PPAR ligand, also
inhibited MMP-1 production in a dose-dependent manner,
with a higher EC50; 3050 M [Fig. 2(b)]. One can argue
that the inhibitory effect of PPAR ligands may be due to
Osteoarthritis and Cartilage Vol. 10, No. 2 103some toxicity, as 15d-PGJ2 was reported to induce such
effects at high concentrations. Using the trypan blue exclu-
sion assay and the MTT salt assay, data showed that
treatment with PPAR ligands at the concentration used
does not affect human synovial Þbroblast viability (data not
illustrated).
To determine at which point 15d-PGJ2 effectively inhib-
ited MMP-1 production in response to IL-1 stimulation,
10 M of 15d-PGJ2 was added simultaneously with IL-1
(time 0), or at intervals (1, 2, 4, 6 and 8 h) after the addition
of IL-1, and the cells were incubated for a total period of
24 h. Following this, MMP-1 production was measured in
the conditioned media. As illustrated in Fig. 3, for 15d-PGJ2
to signiÞcantly inhibit IL-1 induced MMP-1 production, the
compound had to be present early during the incubation
period. Maximum inhibition was obtained when the com-
pound was added during the Þrst 2 h of incubation with
IL-1. The effect became weaker over the next 4 h, andwas lost by 8 h. These results indicate that 15d-PGJ2 may
inhibit an early stage in the IL-1 signaling cascade.15d-PGJ2 INHIBITS IL-1-INDUCED MMP-1 MRNA EXPRESSION
Because transcriptional regulation is considered to be
the major mechanism affecting MMP-1 production, the
effect of 15d-PGJ2 on MMP-1 mRNA was investigated.
Synovial Þbroblasts were stimulated with 100 pg/ml IL-1 in
the presence of increasing concentrations of 15d-PGJ2 for
18 h, and Northern blot analysis performed. Data showed
that 15d-PGJ2 suppresses the MMP-1 mRNA level in a
concentration-dependent fashion (Fig. 4). BRL 49653 also
reduced MMP-1 mRNA expression, but with a less pro-
nounced effect. This is consistent with their effects on
MMP-1 synthesis. These results suggest that PPAR
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Fig. 1. Human synovial Þbroblasts express functional PPAR. (a)
Total RNA (2 g) from three different human synovial Þbroblast
patients were subjected to an RT reaction either with (+) or without
(−) reverse transcriptase. Each reaction was subjected to PCR
with PPAR-, and GAPDH-speciÞc primers. AmpliÞcation products
were resolved in a 2% agarose gel. A 100 bp DNA ladder (marker)
is shown. (b) Human synovial Þbroblasts were transiently trans-
fected with a plasmid construct containing the PPREx3-thymidine
kinase promoter fused to the luciferase reporter gene (2 g), and
pSV4--galactosidase (0.5 g) as a control, using the FuGene
transfection reagent. Cells were treated with or without 15d-PGJ2
(10 M) or BRL 49653 (100 M), and luciferase activitiy deter-
mined. Luciferase activity normalized to -galactosidase activity is
expressed as fold induction, considering 1 as the luciferase activity
of unstimulated transfected cells. Control, ; BrL 49653 (100 M),











































































Fig. 2. PPAR ligands inhibit IL-1-induced MMP-1 production.
Human synovial Þbroblasts (N=4) were incubated with 100 pg/ml
IL-1 in the absence or presence of increasing concentrations
of PPAR ligands (A) 15d-PGJ2 or (B) BRL 49653. Results are
expressed as percentage of the amount of secreted MMP-1 by
IL-1-stimulated cells and are the mean±S.E.M. P values indicate
difference from the IL- treated cells.15d-PGJ2 ATTENUATES THE ACTIVATION OF THE MMP-1 PROMOTER
To determine whether 15d-PGJ2 negatively interferes
with the transcriptional activation of MMP-1, we analysed
the effect of 15d-PGJ2 on the human MMP-1 promoter
activation. Preliminary experiments were carried out with










































Fig. 3. Time-course of MMP-1 production inhibition by 15d-PGJ2.
Human synovial Þbroblasts (N=3) were treated with 100 pg/ml
IL-1 and 15d-PGJ2 (10 M) was added either simultaneously
(time 0) or at different time points after IL-1 (1, 2, 4, 6 and 8 h).
MMP-1 was measured in the supernatants 24 h following the
addition of IL-1. Data are mean±S.E.M. P values indicate difference
from the IL--treated cells.Fig. 4. 15d-PGJ2 represses IL-1 mediated induction of MMP-1 mRNA. Human synovial Þbroblasts (N=3) were treated with 100 pg/ml IL-1
in the absence or presence of increasing concentrations of (A) 15d-PGJ2 or (B) BRL 49653. Total cellular RNA was isolated and subjected
to Northern blot analysis. Right panels are representative Northern blot. Left panels are MMP-1 mRNA levels normalized to GAPDH. Data
are expressed as the percentage of IL-1 control, and are the mean±S.E.M. P values indicate difference from the IL--treated cells.IL-1 and the phorbol ester PMA, both potent activators of
MMP-1 transcription. Data showed that 15d-PGJ2 inhibits
both IL-1- and PMA-induced MMP-1 production. However,
as transfected human synovial Þbroblasts are hyporespon-
sive to IL-1 stimulation, we further assessed the effect of15d-PGJ2 on MMP-1 promoter activation by PMA. Human
synovial Þbroblasts were transfected with the human
MMP-1 promoter fused to the luciferase gene and subse-
quently treated with PMA, and/or the PPAR ligand 15d-
PGJ2. As illustrated in Fig. 5, PMA stimulation up-regulates
the MMP-1 reporter gene expression. In the presence of
15d-PGJ2, the reporter gene activity was signiÞcantly inhib-
ited. Cotransfection with a human PPAR expression vec-
tor reduced both basal and PMA-induced MMP-1 luciferase
activity, likely because of its high level of expression. This
was further reduced in the presence of 15d-PGJ2, suggest-
ing that PPAR might be involved in the inhibitory effect of
15d-PGJ2. These results clearly indicate that 15d-PGJ2
inhibits MMP-1 expression at the transcriptional level, likely
through PPAR activation.15d-PGJ2 INHIBITS AP-1 DNA BINDING ACTIVITY
The Þnding of reduced MMP-1 promoter activity follow-
ing treatment with 15d-PGJ2 suggested that modulation
might occur at the level of transactivating factors that
regulate MMP-1 transcription. The transcription factor AP-1
has been shown to play a critical role in the regulation of
both basal and induced MMP-1 transcription1013. To delin-
eate the possible mechanism by which PPAR ligands
inhibit MMP-1 transcription, we analysed the effect of
15d-PGJ2 on nuclear protein binding to an oligonucleotide
corresponding to the proximal AP-1 site of the human
MMP-1 promoter. As illustrated in Fig. 6, IL-1 stimulated
the basal binding activity about 2.5-fold. 15d-PGJ2 reduced











































Fig. 5. 15d-PGJ2 inhibits the induction of human MMP-1 promoter
activity by PMA. Human synovial Þbroblasts (N=3) were trans-
fected with the -512hMMP1-Luc in the absence or presence of
pSG5-h PPAR. Transfection efficiency was monitored by cotrans-
fecting the cells with pSV40--galactosidase construct. Trans-
fected cells were treated with PMA (100 nM) in the absence or
presence of 15d-PGJ2 (10 M). Luciferase activity was determined
and normalized to -galactosidase expression. Results are
expressed as fold induction, considering 1 as the luciferase activity
of unstimulated transfected cells, and represent the mean±S.E.M. P















































Fig. 6. 15d-PGJ2 inhibits DNA-binding activity of AP-1. Human
synovial Þbroblasts (N=4) were treated with or without 15d-PGJ2
(10 M) for 2 h, followed by the addition of IL-1 (100 pg/ml) for
1 h. Nuclear extracts were prepared and incubated with a
[-32P]ATP-labeled oligonucleotide containing the AP-1 consensus
sequence. SpeciÞcity of binding was conÞrmed using a 50-fold
molar excess of AP-1 (Comp) and mutated (mut Comp) unlabeled
oligonucleotides. The upper panel is an EMSA representative
experiment. The lower panel represents a densitometric scanning
analysis, where data are mean±S.E.M. P values indicate differencefrom the autologous controls as indicated.Discussion
In this study we investigated the expression of PPAR,
and the effect of its activators on the induction of MMP-1 in
human synovial Þbroblasts. We report that PPARmRNA is
expressed in these cells. Moreover, the activation of a
canonical PPRE-Luc transfected into synovial Þbroblasts
with the PPAR natural activator 15d-PGJ2 and the syn-
thetic one BRL 49653, strongly supports the presence of a
functional PPAR in these cells. These results are consist-
ent with recent Þndings showing by Western immunoblot
and immunohistochemistry, that PPAR is produced in
human synovial Þbroblasts35.
Macrophages and T lymphocytes, which play an import-
ant role in joint destruction by the activation of proinßam-
matory cytokine production, which in turn trigger the
release of MMP-1, were found to express PPAR20,21. In
addition, PPAR was also expressed in other cell types
including chondrocytes and osteoclasts23,24,29. The
expression of PPAR in most cells involved in connective
tissue metabolism suggest a potential regulatory role for
this nuclear receptor. In this regard, it was demonstrated
that PPAR activation inhibits the inßammatory response of
macrophages, the production of IL-2 by lymphocytes,
and modulates osteoclast differentiation as well as the
production of nitric oxide (NO) and proteoglycan by
chondrocytes20,21,23,24,29.
To evaluate the role of PPAR in human synovial Þbro-
blasts, we examined the effect of PPAR ligands on IL-1-induced MMP-1 production. Our data showed that two
PPAR agonists, 15d-PGJ2 and BRL 49653, decreased
IL-1-induced MMP-1 release in a dose-dependent man-
ner. To effectively inhibit MMP-1 production, 15d-PGJ2 had
to be added to the cultures within 2 h of IL-1 stimulation.
After this time, the compound began to lose its inhibitory
activity, suggesting an effect over early responses activated
by IL-1. The fact that IL-1 effects are still inhibited 2 h
following induction may reßect the transport and availability
of 15d-PGJ2 in culture medium. 15d-PGJ2 inhibited MMP-1
induction with an EC50 of 35 M, which is well in line with
the reported Kd values for PPAR25,34.
One can argue that the effect of 15d-PGJ2 may be
related to a general cell toxicity. This was not substantiated
by our data, as under our experimental conditions, 15d-
PGJ2 had no impact on cell viability. Kawahito et al.35
recently reported that 15d-PGJ2 induces synovial Þbroblast
apoptosis. Although this latter phenomenon was not
speciÞcally examined in our study, as mentioned above, no
difference in cell viability was found in the presence or
absence of 15d-PGJ2. One possible explanation for this
difference may be the relatively higher 15d-PGJ2 concen-
trations used by the authors. The difference may also lie in
the cell source. Indeed, and in contrast with our study, inboth basal and induced AP-1 binding activity. The speci-
Þcity of the binding was conÞrmed by competition with an
unlabeled wild type and mutant oligonucleotides. These
data suggest that the inhibitory effect of 15d-PGJ2 on
IL-1-induced MMP-1 gene transcription is mediated, at
least in part, by down-regulating AP-1 binding activity.
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